Curis, Inc. Announces Pricing of $8.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules with Existing Healthcare Focused Institutional InvestorsPRNewsWire · Oct 16, 2026 
Curis, Inc. Announces Pricing of $5.6 Million Public OfferingPRNewsWire · Aug 13, 2026 
Curis Doses First Five Patients in TakeAim CLL StudyPRNewsWire · Jul 30, 2026Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 14, 2026 | -$6.95 | -$4.02 | Beat |
| May 12, 2026 | -$5.80 | -$25.00 | Miss |
| Mar 19, 2026 | -$8.72 | $24.60 | Beat |
| Nov 6, 2025 | -$12.40 | -$9.80 | Beat |
| Aug 5, 2025 | -$39.80 | -$13.60 | Beat |
| May 6, 2025 | -$22.80 | -$25.00 | Miss |
